SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to positive trial results for its PoNS device in stroke rehabilitation, sparking community excitement about its potential FDA submission under Breakthrough Device Designation. The community is actively discussing the low float and potential for a short squeeze, while some caution about potential dilution. Broader context includes the company's focus on neuromodulation therapies and its existing FDA approval for multiple sclerosis.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia ($NVDA) is trending amid news of China investigating potential antitrust violations related to a past acquisition, sparking concerns about market access and potential penalties. The community debates the significance of this development, with some viewing it as an opportunity to buy the dip while others express concerns about the stock's vulnerability to negative China-related headlines and potential broader market impacts. Despite the uncertainty, some remain optimistic about Nvidia's long-term prospects, citing its leadership in AI and strong fundamentals.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma is trending as traders anticipate the release of Phase 3 trial data for their lead drug, Efzofitimod, with potential implications for treating pulmonary sarcoidosis; the community is discussing possible outcomes and speculating on a short squeeze, while acknowledging the inherent risks of a binary biotech event; some are closely watching for early data leaks or unusual trading patterns, while others are reviewing past trial data and KOL opinions to inform their investment decisions.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its dedicated community and consistent growth over the past nine months, setting new all-time highs. The community is energized by a current buy contest and anticipates increased exposure with an upcoming listing, as well as an airdrop. Many believe $BROKE.X is undervalued and poised for a significant breakout, emphasizing its resilience and potential in the altcoin space.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid excitement surrounding upcoming presentations at the Quantum World Congress and UK regulatory approval for its acquisition of Oxford Ionics. The community is actively debating whether IONQ can achieve a market capitalization similar to that of NVDA, and many are citing the stock's potential for significant long-term gains while some discuss short-term profit taking.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is surging amid discussions of potential Q3 delivery beats and optimism surrounding future growth areas like robotics and energy storage. Community discussions also highlight Barclays' expectations for delivery growth and debates over the impact of expiring EV credits. Technical analysis suggests a breakout, though some investors remain cautious, citing valuation concerns and potential pullbacks.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to its recent merger with Strive and a strategic shift towards Bitcoin, sparking discussions of a potential short squeeze. The community is focused on high short interest, borrow fees, and the possibility of forced buy-ins, with many anticipating significant price movement. Some traders are experiencing trading restrictions, while others speculate on the impact of potential dilution from warrants.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss its high short interest and potential for a squeeze, with some citing the upcoming Rumble Wallet launch and the Northern Data acquisition as possible catalysts. JD Vance's exclusive on the platform and overall ties to prominent figures are also fueling community speculation. Despite some frustration with the stock's performance, bulls remain optimistic about its long-term potential, particularly with its connections to crypto and a shift towards alternative media.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending due to positive sentiment around nuclear energy deals and potential entry into the US SMR market. Community members are discussing the UK's commitment to nuclear expansion and anticipating further news from upcoming industry events. Increased defense spending and potential partnerships related to AI data centers are also driving interest in the stock.

BlackRock Institutional Trust Company N.A. - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is trending due to a mix of factors, including reactions to Nvidia's potential to resume AI chip sales in China and overall optimism in the semiconductor sector. Community discussions revolve around SOXX's technical indicators, potential pullbacks, and strategies involving leveraged ETFs like SOXL and SOXS. Broader market context includes the AI boom, geopolitical tensions, and upcoming earnings reports from major semiconductor companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atyr Pharma shares fell 1.5% in volatile premarket trade on Monday, with investors on edge ahead of topline results from its pivotal Phase 3 EFZO-FIT trial of efzofitimod. The data is expected any day and will be presented at the European Respiratory Society conference.The 52-week global study, which completed its last patient visits in July, enrolled 268 pulmonary sarcoidosis patients across 85 centers in nine countries. Patients were randomized to monthly intravenous doses of efzofitimod at 3 mg/kg, 5 mg/kg, or placebo.&nbsp;The primary endpoint is steroid reduction from baseline to week 48, with secondary endpoints including symptom relief and lung function. The trial design incorporated a forced steroid taper, a key measure for assessing clinical benefit.Analysts have flagged the readout as a potential inflection point. Jefferies lifted its price target to $17 from $9 last month, citing encouraging earlier-stage data and estimating a 60% probability of statistical success. H.C. Wainwright reiterated a ‘Buy’ rating with a $35 target, Cantor Fitzgerald reaffirmed ‘Overweight’ citing strong statistical power to show steroid reduction, and Leerink Partners maintained an ‘Outperform’ rating with a $16 target.CEO Sanjay Shukla said completing EFZO-FIT, the largest interventional study ever conducted in sarcoidosis, was a milestone for patients who currently rely heavily on corticosteroids despite serious side effects.&nbsp;The company is also studying efzofitimod in systemic sclerosis-related interstitial lung disease in its ongoing Phase 2 EFZO-CONNECT trial.Atyr reported second-quarter results in August with cash, equivalents and investments of $83.2 million as of June 30. Subsequent to the quarter, it raised about $30.7 million through an at-the-market offering.&nbsp;The company said the balance is sufficient to fund operations for a year beyond the EFZO-FIT readout. R&amp;D expenses were $15.4 million in the quarter, driven by trial and manufacturing costs, while G&amp;A expenses totaled $4.9 million.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.One user described the range of possible outcomes as a “bear case” of $2 if the data disappoints, a “base case” of $10–$15 on decent results, and a “bull case” of $25–$35 if topline data are strong enough to spark a squeeze.<stembedurl>https://stocktwits.com/Phantom_Dancer/message/628638414</stembedurl>Another user said they had bought $2 call contracts to limit downside risk, noting that the position would cover losses if the stock fell toward $1.50 while leaving room to benefit if a short squeeze drove the shares higher.<stembedurl>https://stocktwits.com/navyvet1234/message/628639974</stembedurl><a href="https://stocktwits.com/symbol/ATYR">Atyr Pharma’s stock</a> has risen 66.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Atyr Pharma’s stock (ATYR) has risen 66.6% so far in 2025. (Photo credit: Getty Images)

Why Is Atyr Pharma Stock Slipping Premarket?

Investors braced for imminent Phase 3 EFZO-FIT trial results of efzofitimod, with analysts calling it a key inflection point.

Equity

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Current Price	$5.38
Prev Close	$5.26
Open	$5.27
Dividend Yield	0.00%
50-Day Moving Average	$5.36
Beta	0.90
Avg. Volume	3.84M
PE Ratio	-7.56

52-Week High	$7.29
52-Week Low	$1.67
Market Capitalization	$590.86M
EPS (Annual)	-$0.8621
Price to Book	7.48
Revenue Per Employee	$3,983.05
Enterprise Value/EBITDA	N/A

ATYR
aTyr Pharma, Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATYR News

ATYR aTyr Pharma, Inc